DELMAR PHARMACEUTICALS, INC. (NASDAQ:DMPI) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On November 21, 2017, DelMar Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its presentation of positive interim results from a study of VAL-083 in MGMT-unmethylated Recurrent GBM at the conference described below. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.
Item 8.01 Other Events.
On November 17 and November 18, 2017, the Company presented posters at the Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology in San Francisco, California. Copies of the posters are attached as Exhibits 99.2, 99.3 and 99.4 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
DelMar Pharmaceuticals, Inc. ExhibitEX-99.1 2 f8k111717ex99-1_delmarpharma.htm PRESS RELEASE DATED NOVEMBER 21,…To view the full exhibit click here
About DELMAR PHARMACEUTICALS, INC. (NASDAQ:DMPI)
DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
